Why the study?
Are there mechanistic differences in proteomic profiles between acute stress cardiomyopathy and acute myocardial infarction?
Are there mechanistic differences in proteomic profiles between acute stress cardiomyopathy and acute myocardial infarction?
Acute stress cardiomyopathy is characterized by a similar activation of inflammatory, complement, and coagulation pathways as acute myocardial infarction, despite a lesser degree of myocardial necrosis.
Identifies shared inflammatory/pro-thrombotic signatures in SCM and AMI; leaves open causal roles or therapeutic targets.
Stress cardiomyopathy (SCM) is a unique cardiac disorder that more often occurs in women. SCM presents in a similar fashion as acute myocardial infarction (AMI), with chest pain, ECG changes, and congestive heart failure. The primary distinguishing feature is the absence of thrombotic coronary occlusion in SCM. How this reduction in cardiac function occurs in the absence of coronary occlusion remains unknown. Therefore, we tested the hypothesis that a targeted proteomic comparison of patients with acute SCM and AMI might identify relevant mechanistic differences. Blood was drawn in normal controls (n=6), women with AMI (n=12) or women with acute SCM (n=15). Two-week follow up samples were available in AMI (n=4) and SCM patients (n=11). Relative concentrations of 1310 serum proteins were measured in each of the 48 samples using the SOMAscan assay. Women with AMI had greater myocyte necrosis, as reflected by a higher peak Troponin I concentration (AMI 32.03 ± 29.46 vs. SCM 2.68 ± 2.6 ng/mL, p1; q<0.05) between AMI and SCM in the acute or recovery phase. However, when we compared normal controls to patients with AMI, there was differential expression of 35 proteins. When we compared normal controls to patients with SCM, 45 proteins were differentially expressed. In comparison to normal controls, biological processes such as complement, coagulation, and inflammation were activated in both AMI and SCM. There were four proteins that showed a non-significant trend to be increased in acute SCM vs. AMI (NET1, FSTL3, Kallikrein 7, KYNU). Despite a lesser degree of myocardial necrosis than AMI, SCM is characterized by a similar activation of inflammatory, complement, and coagulation pathways. These findings may explain reported thromboembolic complications in the short term and elevated risk of mortality in the long term of SCM.
No takes yet. Share an insight, caveat, or question.
Fitzgibbons et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: